Indication
For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or in women who have received prior endocrine therapy

Medicine details

Medicine name:
abemaciclib (Verzenios)
SMC ID:
SMC2179
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Advice due date:
13 May 2019
SMC meeting date:
02 April 2019
Patient group submission deadline:
04 February 2019